File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Serum beta-2 microglobulin level is elevated in patients with acute coronary syndrome

TitleSerum beta-2 microglobulin level is elevated in patients with acute coronary syndrome
Authors
Issue Date2017
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera
Citation
The 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. In Clinical Therapeutics, 2017, v. 39 n. 8S, p. e52 How to Cite?
AbstractBackground Beta-2 microglobulin (B2M) is a marker of renal dysfunction and immune activation. We previously reported that serum B2M is related to age, renal function, cardiovascular and all-cause mortality in Americans. Acute coronary syndrome (ACS) is a common cause of hospital admission and cardiovascular mortality. We tested the hypothesis that the serum level of B2M is elevated in ACS in a prospective study. Methods We recruited 167 Chinese patients (118 men and 49 women; mean age±SD, 64±13 years), of whom 88 had ACS and 79 were controls matched for age and sex. Serum B2M was measured in an accredited laboratory using a latex-enhanced immunoassay (intra-assay coefficient of variation 3.4%). Results In our patients, the serum B2M level (mean±SE) was 2.27±0.12 µg/mL. Because the upper reference level of serum B2M in our laboratory is 1.42 µg/mL, only 24 subjects (14%) had a serum B2M within the reference range. Serum B2M levels (mean±SE) were 2.52±0.21 in ACS patients and 1.99±0.06 µg/mL in controls (p=0.02). There was no significant correlation between serum B2M and troponin level. Serum B2M correlated with serum creatinine (ρ=0.62, p<0.001), age (Spearman’s ρ=0.52, p<0.001) and male gender (ρ=0.19, p=0.01). Conclusions Serum B2M level is increased in ACS patients. It is also related to age and gender, and the serum level of creatinine but not troponin. Our study shows for the first time that serum B2M is a cardiovascular risk marker in Chinese as it is in Americans. B2M is an established prognostic marker in multiple myeloma and so the test is widely available. A prospective study with long follow-up is warranted to evaluate B2M as a prognostic marker after ACS.
Persistent Identifierhttp://hdl.handle.net/10722/248652
ISSN
2017 Impact Factor: 3.185
2015 SCImago Journal Rankings: 0.997

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMY-
dc.contributor.authorTam, F-
dc.contributor.authorCheung, CL-
dc.contributor.authorLee, SWL-
dc.contributor.authorTsui, MSH-
dc.contributor.authorChan, E-
dc.date.accessioned2017-10-18T08:46:30Z-
dc.date.available2017-10-18T08:46:30Z-
dc.date.issued2017-
dc.identifier.citationThe 13th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Prague, Czech Republic, 24-27 June 2017. In Clinical Therapeutics, 2017, v. 39 n. 8S, p. e52-
dc.identifier.issn0149-2918-
dc.identifier.urihttp://hdl.handle.net/10722/248652-
dc.description.abstractBackground Beta-2 microglobulin (B2M) is a marker of renal dysfunction and immune activation. We previously reported that serum B2M is related to age, renal function, cardiovascular and all-cause mortality in Americans. Acute coronary syndrome (ACS) is a common cause of hospital admission and cardiovascular mortality. We tested the hypothesis that the serum level of B2M is elevated in ACS in a prospective study. Methods We recruited 167 Chinese patients (118 men and 49 women; mean age±SD, 64±13 years), of whom 88 had ACS and 79 were controls matched for age and sex. Serum B2M was measured in an accredited laboratory using a latex-enhanced immunoassay (intra-assay coefficient of variation 3.4%). Results In our patients, the serum B2M level (mean±SE) was 2.27±0.12 µg/mL. Because the upper reference level of serum B2M in our laboratory is 1.42 µg/mL, only 24 subjects (14%) had a serum B2M within the reference range. Serum B2M levels (mean±SE) were 2.52±0.21 in ACS patients and 1.99±0.06 µg/mL in controls (p=0.02). There was no significant correlation between serum B2M and troponin level. Serum B2M correlated with serum creatinine (ρ=0.62, p<0.001), age (Spearman’s ρ=0.52, p<0.001) and male gender (ρ=0.19, p=0.01). Conclusions Serum B2M level is increased in ACS patients. It is also related to age and gender, and the serum level of creatinine but not troponin. Our study shows for the first time that serum B2M is a cardiovascular risk marker in Chinese as it is in Americans. B2M is an established prognostic marker in multiple myeloma and so the test is widely available. A prospective study with long follow-up is warranted to evaluate B2M as a prognostic marker after ACS.-
dc.languageeng-
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera-
dc.relation.ispartofClinical Therapeutics-
dc.rightsPosting accepted manuscript (postprint): © <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleSerum beta-2 microglobulin level is elevated in patients with acute coronary syndrome-
dc.typeConference_Paper-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.emailLee, SWL: drsl@hkucc.hku.hk-
dc.identifier.emailTsui, MSH: mshtsui@hkucc.hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.authorityCheung, CL=rp01749-
dc.identifier.doi10.1016/j.clinthera.2017.05.162-
dc.identifier.hkuros282094-
dc.identifier.volume39-
dc.identifier.issue8S-
dc.identifier.spagee52-
dc.identifier.epagee52-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats